Company / R&D per Share
Mineralys Therapeutics, Inc. R&D per Share History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$3.47
FY2024
5-year range
$1.94 / $5.08
FY2022-FY2024
Trend
+78.6%
vs FY2023
Sector context
#60 of 208
Health Care
What the data says
At $3.47, Mineralys Therapeutics, Inc.'s r&d per share ranks #60 of 208 in the Health Care sector. Declined from $5.08 to $3.47 over the past 2 years.
Based on SEC 10-K filings.
3.47 in FY2024.
Declined from $5.08 to $3.47 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#60 of 208 in Health CareTop 29% of 208This company $3.47 Sector average $28.82
▼
-87.9% below sector average
Key checks
Key Insights
- In FY2024, r&d per share increased 78.6% year-over-year.
- Ranks #60 out of 208 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $3.47 | +78.6% |
| FY2023 | $1.94 | -61.7% |
| FY2022 | $5.08 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026